Donor lymphocyte infusion has been used in the management of relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.
The incidence of GVHD can also be reduced by starting with low doses of donor cells and “escalating” subsequent doses as required. However, the identification ...
Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood. 2000 ...
Jul 2, 2021 · Prophylactic or preemptive low-dose azacitidine and donor lymphocyte infusion to prevent disease relapse following allogeneic transplantation.
Jul 15, 2002 · Donor lymphocyte infusion (DLI) can produce durable remissions in patients with chronic myelogenous leukemia (CML) who have a relapse after an allogeneic stem ...
The incidence of GVHD can also be reduced by starting with low doses of donor cells and “escalating” subsequent doses as required. However, the ...
Jan 5, 2023 · If DLI is administered earlier than 6 months after transplant, the starting cell dose should be adjusted on a case-by-case basis to minimize the ...
This group concluded that doses of 1 x 107 cells/kg were a reasonable starting point, with the option of escalating doses with subsequent infusions to achieve ...
Comparison of single-dose and · escalating-dose regimens of donor lymphocyte infusion for relapse · after allografting for chronic myeloid leukemia. Blood. 2000 ...
Feb 15, 2004 · Escalating doses of CD3+ lymphocytes were administered at starting a dose of 1 × 106 T cells/kg. Increasing doses were administered at 3-month ...
